Sugi Predict

Sugi Predict / Compounds / SCHEMBL377491

SCHEMBL377491

SCHEMBL377491

CC(C)(C)OC(=O)N1CCN(Cc2ccc([N+](=O)[O-])cc2)CC1

nearest known ligand 0.67

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.67
▸ LMNA P02545 3/20 0.67
▸ MAPT P10636 3/20 0.67
▸ MGLL Q99685 1/20 0.60
▸ KDM4E B2RXH2 6/20 0.58
▸ SMN1; SMN2 Q16637 5/20 0.56
▸ NPC1 O15118 2/20 0.56
▸ RAB9A P51151 2/20 0.56
▸ NR2F2 P24468 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ GALR3 O60755 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.53
▸ KCNJ1 P48048 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22529564 0.90 ALDH1A1 (0.56) ALDH1A1LMNAMAPTMGLLKDM4E
SCHEMBL4573720 0.88 KCNJ1 (0.65) ALDH1A1LMNAMAPTKCNJ1
SCHEMBL15987536 0.86 KCNJ1 (0.63) ALDH1A1LMNAMAPTMGLLKCNJ1
SCHEMBL30024568 0.86 ALDH1A1 (0.64) ALDH1A1LMNAMAPTMGLLKDM4E
SCHEMBL5387829 0.86 ALDH1A1 (0.64) ALDH1A1LMNAMAPTMGLLKDM4E
SCHEMBL2388312 0.85 ALDH1A1 (0.67) ALDH1A1LMNAMAPTKDM4ESMN1; SMN2
SCHEMBL12195291 0.85 KDM4E (0.56) ALDH1A1LMNAMAPTMGLLKDM4E
SCHEMBL16656263 0.85 KDM4E (0.56) ALDH1A1LMNAMAPTMGLLKDM4E
SCHEMBL5724167 0.85 ALDH1A1 (0.67) ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL3142046 0.85 MGLL (0.56) ALDH1A1LMNAMAPTMGLLKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4640686-A1 DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Innocure Therapeutics, Inc. (KR) 2025-10-29 — — EP disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 — — US disclosed
US-20250320205-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 — — US disclosed
US-20250320206-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 — — US disclosed
EP-4594318-A1 AKT1 MODULATORS Alterome Therapeutics, Inc. (US) 2025-08-06 — — EP disclosed
US-20250092040-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2025-03-20 — — US disclosed
US-20250041429-A1 COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF UBIX THERAPEUTICS, INC. (KR) 2025-02-06 — — US disclosed
EP-4428130-A1 COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF Ubix Therapeutics, Inc. (KR) 2024-09-11 — — EP disclosed
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 — — US disclosed
EP-1224170-A1 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT Boehringer Ingelheim Pharma KG (DE) 2002-07-24 — — EP disclosed
WO-2002036564-A1 SULFONYLAMINO SUBSTITUTED 3-(AMINOMETHYLIDE)-2-INDOLINONES AS CELL PROLIFERATION INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-05-10 — — WO disclosed
US-6319918-B1 FOR LYMPHOMA OR SOLID TUMORS TREATMENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-11-20 — — US disclosed
EP-1100779-A1 SUBSTITUTED INDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS Boehringer Ingelheim Pharma KG (DE) 2001-05-23 — — EP disclosed
WO-2001027081-A1 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-04-19 — — WO disclosed
US-6169106-B1 ANTITUMOUR AGENTS BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-01-02 — — US disclosed
WO-1999062882-A1 SUBSTITUTED INDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA KG (DE) 1999-12-09 — — WO disclosed
EP-0369627-B1 Pyrimidinedione derivative compounds, method of producing the same and antiarrythmic agents containing the same MITSUI TOATSU CHEMICALS (JP) 1994-12-21 — — EP disclosed
US-5008267-A Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1991-04-16 — — US disclosed
EP-0369627-A2 Pyrimidinedione derivative compounds, method of producing the same and antiarrythmic agents containing the same MITSUI TOATSU CHEMICALS, Inc. (JP) 1990-05-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239797-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 ALDH1A1 4692/4885LMNA 3201/4885MAPT 1885/4885
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 ALDH1A1 959/4885LMNA 2978/4885MAPT 1017/4885
US-20250041429-A1 COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF BTK, LYN, SYK ALDH1A1 4704/4885LMNA 4396/4885MAPT 3790/4885
US-20250320205-A1 STAT6 DEGRADERS STAT6, STAT1, STAT5B ALDH1A1 1225/4885LMNA 2666/4885MAPT 1034/4885
US-20250092040-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 ALDH1A1 4692/4885LMNA 3201/4885MAPT 1885/4885
US-20250320206-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 ALDH1A1 959/4885LMNA 2978/4885MAPT 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.